11. 重症筋無力症 Myasthenia gravis Clinical trials / Disease details
臨床試験数 : 315 / 薬物数 : 232 - (DrugBank : 77) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05039190 (ClinicalTrials.gov) | September 10, 2021 | 29/8/2021 | A Study to Evaluate Thefficacy and Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized MG Patients | A Multicenter, Randomized, Double-blind, Placebo-controlled, Seamless and Group Sequential Phase 2/3 Study to Evaluate the Efficacy and Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis | Myasthenia Gravis | Drug: HBM9161 Injection (680mg);Drug: Placebos | Harbour BioMed (Guangzhou) Co. Ltd. | NULL | Not yet recruiting | 18 Years | 99 Years | All | 144 | Phase 3 | China |